Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 2/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143612 | 0.86 | BRD4 (0.33) | CHEK1CHEK2TTKFYNCCNC | |
| SCHEMBL29285150 | 0.81 | DGAT1 (0.38) | DGAT1CHEK1CHEK2 | |
| SCHEMBL22075678 | 0.80 | CYP11B1 (0.43) | DGAT1CYP11B1CYP11B2 | |
| SCHEMBL26693782 | 0.80 | CYP11B1 (0.51) | DGAT1CYP11B1CYP11B2 | |
| SCHEMBL23718770 | 0.78 | IDO1 (0.41) | DGAT1CYP11B1CYP11B2 | |
| SCHEMBL203831 | 0.78 | CYP11B1 (0.48) | DGAT1CYP11B1CYP11B2 | |
| SCHEMBL13070711 | 0.78 | DGAT1 (0.38) | DGAT1CYP11B1CYP11B2 | |
| SCHEMBL4062723 | 0.78 | CYP11B1 (0.50) | DGAT1CYP11B1CYP11B2 | |
| SCHEMBL30877441 | 0.77 | BAZ2B (0.38) | DGAT1CCNCCDK8CYP11B1CYP11B2 | |
| SCHEMBL31403102 | 0.75 | DGAT1 (0.41) | DGAT1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938261-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2766359-B9 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES | AMBIT BIOSCIENCES CORP (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160362405-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452167-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2766359-B1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES | AMBIT BIOSCIENCES CORP (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150196566-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-07-16 | — | — | US | disclosed |
| US-8952058-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2766359-A2 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES | Ambit Biosciences Corporation (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013056070-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362405-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FLT3, PDGFRB, PDGFRA | DGAT1 3769/4885CHEK1 730/4885CHEK2 234/4885 |
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FLT3, PDGFRB, PDGFRA | DGAT1 3769/4885CHEK1 730/4885CHEK2 234/4885 |
| US-20150196566-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FLT3, PDGFRB, PDGFRA | DGAT1 3769/4885CHEK1 730/4885CHEK2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.